1-3 of 3
Sarah Broering
Close
Sort by
Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 3104.
https://doi.org/10.1182/blood.V110.11.3104.3104
Published: 2007
Journal Articles

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

Kristie A. Blum, MD, Donn Young, PhD, Sarah Broering, Margaret S. Lucas, Thomas S. Lin, MD, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 2833.
https://doi.org/10.1182/blood.V108.11.2833.2833
Published: 2006
Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Thomas S. Lin, James T. Dalton, Di Wu, Mitch A. Phelps, Beth Fischer, Mollie Moran, Kristie A. Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J. Schaaf, Amy J. Johnson, David M. Lucas, Nyla A. Heerema, Gerard Lozanski, Donn C. Young, Jose-Ramon Suarez, A. Dimitrios Colevas, Michael R. Grever
Journal: Blood
Blood (2006) 109 (2): 399–404.
https://doi.org/10.1182/blood-2006-05-020735
Published: 2006